Epcoritamab Approved in China for Follicular Lymphoma, Bringing a New CD20×CD3 Bispecific Therapy Option
On May 15, 2026, AbbVie announced that its CD20×CD3 bispecific antibody — Epkinly (Epcoritamab) —…
News
Modern Cancer Treatment in China: An International Guide to CAR-T, Immunotherapy, and Emerging Therapies
Key Takeaways Understand the overall system: Modern cancer treatment in China has developed into a…
Complete Guide to Cancer Treatment in China for International Patients
A cancer diagnosis often brings many important questions.Which treatment option is most suitable? Which hospital…
Top 10 Hospitals in China for International Patients
Key Takeaways International Medical Services: More major Chinese hospitals have established international medical centers, with…
2026 Gastric Cancer Treatment Drug Guide: Latest Dual-Target Therapies, 12 Approved Treatments, and 5 Emerging Technologies
Since the beginning of 2026, the field of gastric cancer treatment has witnessed a major…
China Innovative Drug Approvals April 2026: 6 Approved, 5 by Chinese Companies
April 2026 marked another milestone for China innovative drug approvals April 2026, as the country…
Drug Shortages by Country Causes and Supply Chain Solutions
From emergency medicines to chronic disease treatments, from anti-infectives to oncology therapies, instability in the…
Generic Upadacitinib Approved in China, Marking the Start of JAK Inhibitor Competition
On April 27, 2026, the National Medical Products Administration (NMPA) announced that Jiangsu Huayang Pharmaceutical’s…
RNA Therapeutics for Cardiovascular Disease: PCSK9, Lp(a) and Next-Gen Drug Pipeline (2026)
RNA therapeutics for cardiovascular disease are emerging as a transformative strategy for long-term disease management.…
Approved Immune Checkpoint Inhibitors in China: PD-1, PD-L1, CTLA-4 and Bispecific Antibodies
Immune checkpoint inhibitors (ICIs) restore T-cell–mediated antitumor immunity by blocking key regulatory pathways such as…